Table 2 |
||||
|
c-erbB-2 score evaluations |
||||
|
c-erbB-2 score |
||||
|
|
||||
|
Negative n (%) |
Positive n (%) |
P† |
||
|
|
||||
|
Menstrual Status |
Premenopausal |
16 (72,7) |
6 (27,3) |
|
|
Postmenopausal |
43 (86) |
7 (14) |
0,177 |
|
|
|
||||
|
Histological Grade |
Grade 1 |
22 (88) |
3 (12) |
0,484 |
|
Grade 2 |
30 (76,9) |
9 (23,1) |
||
|
Grade 3 |
7 (87,5) |
1 (12,5) |
||
|
|
||||
|
Invasion Depth |
<1/2 |
31 (75,6) |
10 (24,4) |
0,243 |
|
>1/2 |
23 (92) |
2 (8) |
||
|
Limited to endometrium |
5 (83,3) |
1 (16,7) |
||
|
|
||||
|
Lymph Node Status |
Positive |
3 (75) |
1 (25) |
0,615 |
|
Negative |
28 (93,3) |
2 (6,7) |
||
|
|
||||
|
Stage |
I |
26 (92,9) |
2 (7,1) |
|
|
II |
1 (100) |
0 (0) |
||
|
III |
4 (80) |
1 (20) |
||
|
|
||||
|
Estrogen |
Positive |
52 (85,2) |
9 (14,8) |
0,086 |
|
Negative |
7 (63,6) |
4 (36,4) |
||
|
|
||||
|
Progesterone |
Positive |
51 (86,4) |
8 (13,6) |
0,035 |
|
Negative |
8 (61,5) |
5 (38,5) |
||
|
|
||||
|
Survival |
Alive |
36 (81,82) |
8 (18,18) |
0,215 |
|
Death |
5 (100) |
0 (0) |
||
|
|
||||
|
†: Chi square test. p < 0,05 significant; p > 0,005 insignificant |
||||
|
Gul et al. Diagnostic Pathology 2010 5:13 doi:10.1186/1746-1596-5-13 |
||||
